GlassScriptPhysician profile
Raziuddin Ahmed
NPI 1952562407
$8,185.60
in general payments reported to CMS, 2019-2025
43 companies · $1,980 in 2025
The $1,980 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $812 · 2021: $794 · 2022: $1,147 · 2023: $1,116 · 2024: $1,293 · 2025: $1,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,289 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,288.66 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,155.15 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $954.84 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $631.71 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $596.30 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Harmony Biosciences LLC | $551.63 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $467.12 | 2021-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.17 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Genzyme Corporation | $360.75 | 2019-2025 | |
| Electromed, INC. | $350.21 | 2019-2025 | Smartvest |
| Grifols USA, LLC | $253.90 | 2019-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $251.41 | 2022-2025 | Acthar |
| Insmed, INC. | $198.73 | 2023-2025 | Arikayce |
| Amgen INC. | $192.47 | 2022-2025 | Tezspire |
| Optinose US, INC. | $183.79 | 2020-2022 | |
| Philips North America LLC | $164.93 | 2019-2025 | (Ak6) Vest Therapy, Home Pi Undivided, (2383) Sleepundivided |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $151.84 | 2022-2024 | Avycaz, Teflaro |
| United Therapeutics Corporation | $122.62 | 2019-2023 | Orenitram, Tyvaso |
| Verona Pharma, INC. | $112.68 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $111.78 | 2019-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $91.91 | 2022-2025 | Winrevair |
| Janssen Pharmaceuticals, INC | $90.34 | 2020 | |
| Circassia INC. | $86.07 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $72.38 | 2020-2023 | Xywav |
| Ethicon INC. | $66.46 | 2025 | Monarch Platform |
| Bayer Healthcare Pharmaceuticals INC. | $64.20 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $63.76 | 2022-2023 | |
| Lilly USA, LLC | $51.76 | 2025 | Zepbound, Mounjaro |
| Sunovion Pharmaceuticals INC. | $43.89 | 2019 | |
| Inogen, INC. | $43.44 | 2020-2022 | |
| Tactile Systems Technology INC | $30.60 | 2023 | Flexitouch Plus, Entre Plus |
| Baxter Healthcare | $28.42 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Shionogi INC | $28.23 | 2021 | |
| Ani Pharmaceuticals, INC. | $27.93 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $27.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.61 | 2020 | |
| Axsome Therapeutics, INC. | $24.93 | 2023 | Sunosi |
| Sanofi-Aventis U.S. LLC | $23.08 | 2019 | |
| Vanda Pharmaceuticals INC. | $19.53 | 2019 | |
| Sanofi Pasteur INC. | $18.63 | 2019 | |
| Pulmonx Corporation | $16.23 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Resmed Corp | $16.01 | 2023 | |
| Phadia US INC. | $14.64 | 2025 | Immunocap |
| Fisher & Paykel Healthcare INC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raziuddin Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.